David Gionco
Director of Finance/CFO chez STEMLINE THERAPEUTICS, INC.
Profil
David G.
Gionco is currently the Chief Accounting Officer & Senior VP-Finance at Stemline Therapeutics, Inc. He previously worked as the Finance Director at Progenics Pharmaceuticals, Inc. in 2003-2004, the Chief Financial Officer, Treasurer & VP at Savient Pharmaceuticals, Inc. in 2011, the Controller, Head-Finance & Accounting at Merck & Co., Inc. from 1994-1997, the Controller at Medco Health Solutions, Inc., and the Chief Financial Officer & Controller at Odyssey Pharmaceuticals in 2004-2006.
He holds an MBA from Rutgers State University of New Jersey and an undergraduate degree from Fairleigh Dickinson University.
Postes actifs de David Gionco
Sociétés | Poste | Début |
---|---|---|
STEMLINE THERAPEUTICS, INC. | Director of Finance/CFO | 16/01/2014 |
Anciens postes connus de David Gionco
Sociétés | Poste | Fin |
---|---|---|
Odyssey Pharmaceuticals | Director of Finance/CFO | 01/02/2006 |
PROGENICS PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/08/2004 |
MERCK & CO., INC. | Director of Finance/CFO | 01/03/1997 |
Medco Health Solutions, Inc.
Medco Health Solutions, Inc. Medical/Nursing ServicesHealth Services Medco Health Solutions, Inc. retails drugs, pharmaceuticals and other health products through online. The firm provides pharmacy services which are designed for private and public employers, health plans, labor unions government agencies of all sizes and individuals. The company was founded in June 1983 and is headquartered in Franklin Lakes, NJ. | Comptroller/Controller/Auditor | - |
SAVIENT PHARMACEUTICALS INC | Director of Finance/CFO | 12/09/2011 |
Formation de David Gionco
Rutgers State University of New Jersey | Masters Business Admin |
Fairleigh Dickinson University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Medco Health Solutions, Inc.
Medco Health Solutions, Inc. Medical/Nursing ServicesHealth Services Medco Health Solutions, Inc. retails drugs, pharmaceuticals and other health products through online. The firm provides pharmacy services which are designed for private and public employers, health plans, labor unions government agencies of all sizes and individuals. The company was founded in June 1983 and is headquartered in Franklin Lakes, NJ. | Health Services |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Odyssey Pharmaceuticals | Health Technology |